Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients

Psychiatry and Clinical Neurosciences

Volumn 54, Issue 4, 2000, Pages 467-478

  Ishigooka, Jun ^a,b   Murasaki, Mitsukuni ^a   Miura, Sadanori ^a   Kamijima, Kunitoshi ^c   Koyama, Tsukasa ^d   Kudo, Yoshio ^e   Machiyama, Yukiteru ^f   Nakajima, Teruo ^g   Nakane, Yoshifumi ^h   Nishimura, Tsuyoshi ⁱ   Ogura, Chikara ^j   Saito, Masami ^k   Sakai, Toshiaki ^l   Toru, Michio ^m   Watanabe, Shosuke ⁿ   Yagi, Gohei ^o   Yamauchi, Toshio ^p   Yamawaki, Shigeto ^q  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHOWA UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e Haruki Hospital

^f GUNMA UNIVERSITY   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^h NAGASAKI UNIVERSITY   (Japan)

ⁱ OSAKA UNIVERSITY   (Japan)

^j UNIVERSITY OF THE RYUKYUS   (Japan)

^k KANSAI MEDICAL UNIVERSITY   (Japan)

^l OSAKA MEDICAL COLLEGE   (Japan)

^m TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

ⁿ KAWASAKI MEDICAL SCHOOL   (Japan)

^o KEIO UNIVERSITY   (Japan)

^p SAITAMA MEDICAL UNIVERSITY   (Japan)

^q HIROSHIMA UNIVERSITY   (Japan)

more..

Author keywords

Atypical antipsychotic; Clinical open label trial; Olanzapine; Optimal dose; Schizophrenia

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; OUTCOMES RESEARCH; QUALITY OF LIFE; RATING SCALE; RECEPTOR AFFINITY; SCHIZOPHRENIA; SCORING SYSTEM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0033832277     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2000.00738.x     Document Type: Article

References (27)

1. The mechanism of action of clozapine in relation to its clinical advantages
2. Radioreceptor binding profile of the atypical antipsychotic olanzapine
3. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
4. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium
5. Review of the preclinical pharmacology of olanzapine: A MARTA class antipsychotic
6. Multi-acting receptor targeted agent (MARTA) - Dirty or rich?
7. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial
8. Phase I study of LY170053 (Olanzapine) - Single and multiple dose studies
9. Statistical issues of cumulative response rates in a dose titration study
10. The analysis of a titration study
11. Clinical evaluation of a new antipsychotic, perospirone HCl on schizophrenia - A comparative double-blind study with haloperidol
12. Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl on schizophrenia - A comparative double-blind study with mosapramine HCl
13. Efficacy of a new antipsychotic risperidone, on schizophrenia - A Comparative double-blind study with haloperidol
14. Clinical evaluation of risperidone in schizophrenia: A double blind comparative study of risperidone with clocapramine
15. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
16. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
17. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia
18. A rating scale for extrapyramidal side effects
19. A rating scale for drug-induced akathisia
20. A discontinuation study of combined antiparkinson drugs after switching from conventional neuroleptics to a new antipsychotic, risperidone, in chronic schizophrenia
21. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial
22. Clozaril
23. Olanzapine-induced agranulocytosis
24. Weight gain associated with neuroleptic medication: A review
25. Clozapine-induced weight gain: Prevalence and clinical relevance
26. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multicentre, double-blind, parallel-group study versus haloperidol